Clinical Data to sell testing unit to Transgenomic for $15.4 million

Acquisition includes a suite of proprietary genetic commercial tests, certain proprietary biomarker assays, and the CLIA-certified laboratory operations of Clinical Data
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
OMAHA, Neb.—Transgenomic Inc. announced Nov. 30 the signing of a definitive agreement to acquire the diagnostic business of Clinical Data Inc. for $15.4 million. This acquisition includes a suite of proprietary geneticcommercial tests, certain proprietary biomarker assays, and theCLIA-certified laboratory operations of Clinical Data.Closing of the transaction is subject to customary regulatory approvalsand closing conditions.
 
"This is a significanttransaction for our company. It brings a well established and growingmolecular diagnostic business addition, a substantial and establishedrevenue base and validated new biomarker assays along with a talenteddiagnostic team," says Craig Tuttle, CEO of Transgenomic. "Importantly, the acquisition provides us with multiplegrowth opportunities through continued growth of the eleven test FAMILIONproduct portfolio of molecular assays for inherited cardiac disordersplus several proprietary assays for testing patients' response toimportant cancer treatments and patients' drug metabolism of a varietyof drugs. This acquisition will significantly improve our competitiveposition and enhance our customer support and patient care capabilities."
 
Clinical Data'sdiagnostic business includes: The FAMILION family of 11commercialized proprietary tests; contracts with private and governmenthealth insurers for test reimbursement with coverage policies that offeraccess to genetic testing for an estimated 280 million patients;established academic and medical society guidelines, as well as theHeart Failure Society of America guidelines, that include genetictesting that can be identified by FAMILION tests that detectgenetic mutations that cause cardiac channelopathies orcardiomyopathies; pipeline opportunities that include the Fc gammareceptor family of oncology tests and a clopidogrel response test;marketing resources; testing and customer service capabilities;intellectual property and rights; a state-of-the art facility; andequipment.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue